Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study

26 Mar 2025

Abstract excerpt

BACKGROUND: Due to the low incidence of BRAF mutations, limited data is available about their prevalence and clinical characteristics. Moreover, comparative real-world efficacy of dabrafenib combined with trametinib versus other treatment regimens, especially in Chinese patients, is also lacking. METHODS: Patients who had BRAF genetic testing from the Lung Cancer Big Data Precise Treatment Collaboration Group...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Share to Lung Cancer Treatments and Mutations
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40138888
DOI: 10.1016/j.ebiom.2025.105652

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre studyPMID 40138888Read ↗

The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.Semantic proximity Read ↗

Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia).Semantic proximity Read ↗

Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAFV600E mutation-positive metastatic non-small cell lung cancerSemantic proximity Read ↗

Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLCSemantic proximity Read ↗

A real world analysis of secondary BRAF variations after targeted therapy resistance in driver gene positive NSCLC.Semantic proximity Read ↗

KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study.Semantic proximity Read ↗

Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.Semantic proximity Read ↗

Prevalence and breakdown of non-small cell lung cancer BRAF driver mutations in a large UK cohort.Semantic proximity Read ↗

Real-World Efficacy of First- and Second-Generation EGFR TKIs in NSCLC with EGFR Co-mutations: A Vietnamese Cohort StudySemantic proximity Read ↗

Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study.Semantic proximity Read ↗

Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient.Semantic proximity Read ↗

[Expert consensus on the diagnosis and treatment in advanced non-small cell lung cancer with BRAF mutation in China].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.